CCCC vs KYMR
CCCC: Clinical-stage biotech deploying its proprietary TORPEDO platform to develop first-in-class small-molecule targeted protein degraders for oncology, neuroinflammation, and neurodegeneration. KYMR: Kymera Therapeutics is a pioneer in targeted protein degradation, developing oral small-molecule drugs that mimic the efficacy of injectable biologics for inflammatory diseases.
Side-by-side fundamentals
| Metric | CCCC | KYMR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.74 | $110.34 | |
| Market cap as of 2026-07-23 | $414M | $9.1B | |
| PEG as of 2026-07-23 | n/a | -2.09 | |
| Net margin as of 2026-07-23 | -297.8% | -612.0% | CCCC higher |
| Operating margin as of 2026-07-23 | -326.6% | -697.7% | CCCC higher |
| ROE as of 2026-07-23 | -50.7% | -25.0% | KYMR higher |
| ROA as of 2026-07-23 | -33.2% | -22.3% | KYMR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | CCCC lower |
| Revenue growth (YoY) as of 2026-07-23 | -12.4% | -12.6% | CCCC higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | -5.7% | CCCC higher |
| Beta as of 2026-07-23 | 2.92 | 1.94 | |
| 1-year return as of 2026-07-22 close | +68.7% | +151.2% | KYMR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.